IL-17 A and IL-17 F Inhibition in the Treatment of Psoriasis and Psoriatic Arthritis - New Developments: Online CME Activity

About
Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

IL-17 A and IL-17 F Inhibition in the Treatment of Psoriasis and Psoriatic Arthritis - New Developments

This CME presentation was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from UCB.

April Armstrong, MD, MPH

Moderator

Professor of Dermatology
Associate Dean of Clinical Research
University of Southern California
Los Angeles, CA

Richard Langley, MD

Faculty

Professor of Medicine
Director of Research, Division of Clinical Dermatology and Cutaneous Science
Dalhouise University
Halifax, NS

Bruce Strober, MD, PhD

Faculty

Professor and Chairman
Department of Dermatology
Uconn Health Center
Farmington, CT

Upon completion of this activity, the participant should be better able to:

Understand the mechanism of action of IL-17 inhibitors
Evaluate the safety and efficacy profile of IL-17 inhibitors, including IL-17 A and IL-17 F inhibitors
Identify what type of patients would benefit from available and future IL-17 treatments

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nevada, Reno School of Medicine and Dermatology University. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONFLICTS OF INTEREST/DISCLOSURES

April W. Armstrong, MD, MPH

Grant/Research Support: BMS, Dermavant, Dermira, Lilly, Galderma, Janssen, Kyowa Hakko Kirin, LEO, Pfizer, UCB
Speakers’ Bureau or Honoraria: AbbVie, BMS, Dermavant, Lilly, Janssen, LEO, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme Regeneron, SUN, AbbVie

Richard G. B. Langley, MD

Consultant: AbbVie, Amgen, Celgene, Boehringer-Ingelheim, Lilly, Novartis, LEO, UCB

Bruce E. Strober MD

Grant/Research Support: Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara Therapeutics, Novartis
Consultant: AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, BMS, Connect Biopharma, Dermavant, Dermira, Equillium, Janssen, Leo, Lilly, Meji Seika Pharma, Mindera, Novartis, Pfizer, GSK, UCB, SUN, Ortho Dermatologics, Sanofi Genzyme Regeneron
Speakers’ Bureau or Honorarium: AbbVie, Amgen, Lilly, Janssen, Sanofi Genzyme Regeneron